Article Text

This article has a correction. Please see:

other Versions

Download PDFPDF

The impact of T-cell co-stimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept
  1. Paul Emery1,*,
  2. Patrick Durez2,
  3. Maxime Dougados3,
  4. Clarence W Legerton4,
  5. Jean-Claude Becker5,
  6. George Vratsanos5,
  7. Harry K Genant6,
  8. Charles G Peterfy7,
  9. Pranab Mitra5,
  10. Sandra Overfield5,
  11. Keqin Qi5,
  12. René Westhovens8
  1. 1 University of Leeds, United Kingdom;
  2. 2 UCL, St Luc, Belgium;
  3. 3 Hopital Cochin, Descartes University, France;
  4. 4 Low Country Research Centre, United States;
  5. 5 Bristol-Myers Squibb, United States;
  6. 6 University of California/Synarc, United States;
  7. 7 Synarc, United States;
  8. 8 UZ Gasthuisberg, Belgium
  1. Correspondence to: Paul Emery, Section of Musculoskeletal Disease, University of Leeds, Section of Musculoskeletal Disease, Second Floor, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, United Kingdom; p.emery{at}


Background: Several agents provide treatment for established RA, but a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or very early RA.

Methods: In this double-blind, Phase II, placebo-controlled 2-year study, anti-CCP2-positive patients with UA (not fulfilling the ACR criteria for RA) and clinical synovitis of ≥2 joints were randomized to abatacept (~10 mg/kg) or placebo for 6 months, then study drug was terminated. The primary endpoint was development of RA (by ACR criteria) at Year 1. Patients were monitored by radiography, MRI, CCP2, RF, DAS28 and 28-joint count over 2 years.

Results: At Year 1, 12/26 (46%) abatacept-treated versus 16/24 (67%) placebo-treated patients developed RA (difference [95% CI] –20.5% [–47.4, 7.8]). Adjusted mean changes from baseline to Year 1 in Genant-modified Sharp radiographic scores for abatacept- versus placebo-treated patients, respectively, were: 0 versus 1.1 for TS, and 0 versus 0.9 for ES. Mean changes from baseline to Year 1 in MRI erosion, osteitis and synovitis scores were 0, 0.2 and 0.2, respectively, versus 5.0, 6.7 and 2.3 in the abatacept versus placebo groups. Safety was comparable between groups; serious AEs occurred in one patient (3.6%) in each group.

Conclusion: Abatacept delayed progression of UA/very early RA in some patients. An impact on radiographic and MRI inhibition was observed, which was maintained for 6 months after therapy cessation. This suggests that it is possible to alter the progression of RA by modulating T-cell responses at a very early stage of disease.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Linked Articles

  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism